Interventional oncology ablation is a minimally invasive procedure to treat solid cancers. In this procedure, special probes are used to burn or freeze cancer tumors without the usual surgery.
Market Dynamics
The increasing incidence of cancer is expected to drive the growth of global interventional oncology ablation market over the forecast period.
For instance, according to the World Health Organization statistics published in March 2021, cancer is the second leading cause of death globally and is responsible for about 10 million deaths per year, and globally about one in six deaths are due to cancer. Furthermore, according to the same source, an estimated 9.6 million deaths occurred due to cancer in 2018 globally.
Key features of the study:
- This report provides in-depth analysis of the global interventional oncology ablation market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global interventional oncology ablation market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Boston Scientific Corporation, Johnson & Johnson, Medtronic Plc, Varian Medical Systems, Inc., EDAP TMS S.A., AngioDynamics, CASCINATION AG, Merit Medical Systems, Inc., STARmed Co., and Biomedical Srl.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global interventional oncology ablation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interventional oncology ablation market
Detailed Segmentation:
- Global Interventional Oncology Ablation Market, By Technology:
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- Global Interventional Oncology Ablation Market, By Indication:
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- Global Interventional Oncology Ablation Market, By End User:
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- Global Interventional Oncology Ablation Market, By Region:
- North America
- By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- By Indication
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- By Country
- Latin America
- By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- By Indication
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- By Indication
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- By Indication
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- By Indication
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- By Indication
- Liver Cancer
- Kidney cancer
- Lung Cancer
- Others
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Boston Scientific Corporation*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Johnson & Johnson
- Medtronic Plc
- Varian Medical Systems, Inc.
- EDAP TMS S.A.
- AngioDynamics
- CASCINATION AG
- Merit Medical Systems, Inc.
- STARmed Co.
- Biomedical Srl
“*” marked represents similar segmentation in other categories in the respective section.
